Advertisement
U.S. markets closed

Indaptus Therapeutics, Inc. (INDP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3600+0.2700 (+12.92%)
At close: 04:00PM EST
2.3900 +0.03 (+1.27%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close2.0900
Open2.3200
Bid2.3900 x 900
Ask2.3900 x 1000
Day's Range2.1200 - 2.6000
52 Week Range1.5000 - 4.0800
Volume3,366,338
Avg. Volume13,806
Market Cap19.826M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-2.0200
Earnings DateMay 03, 2024 - May 07, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INDP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Indaptus Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/13/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

    • Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort • Single dose cohort data expected to be published at a scientific conference in 2024 NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces positive results from the second

  • GlobeNewswire

    Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference

    NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today that Jeffrey A. Meckler, Chief Executive Officer, and Nir Sassi, Chief Financial Officer, will present a corporate update at the 2024 BIO CEO & Investor Conference. The conference is being held on February 26 – 27, 2024 at the New York Marriott Marquis. Presentation Date: Monday, Fe

  • GlobeNewswire

    Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

    NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn